Question Assignment description
1. Bias is a significant downside in our efforts to judge health screening packages. What are the main sources of bias which have to be thought-about on this regard, and what will be executed to scale back bias in the analysis of health screening packages.
2. Nice emphasis is positioned in American drugs right this moment on the privateness and confidentiality of sufferers. This emphasis was assured by the passage of HIPAA, the Health Insurance coverage Portability and Accountability Act, by Congress. How will we guarantee that privateness and confidentiality proceed to be protected when sufferers (or affected person information) are concerned in epidemiological analysis? How will we govern entry to epidemiological information?